<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">97% (N = 6945) of the total Rotterdam Study participants would be eligible for any trial in the first analysis, while this percentage dropped to 43% (N = 3107) in the second analysis. Among the 5781 participants at high-risk of severe COVID-19, 96% (N = 5564) would be eligible for any trial in the first analysis and 36% (N = 2102) in the second analysis (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>).
</p>
